{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T11:38:39Z","timestamp":1768909119814,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,6,9]],"date-time":"2011-06-09T00:00:00Z","timestamp":1307577600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s12032-011-9999-4","type":"journal-article","created":{"date-parts":[[2011,6,8]],"date-time":"2011-06-08T11:25:21Z","timestamp":1307532321000},"page":"1916-1920","source":"Crossref","is-referenced-by-count":29,"title":["Prognostic significance of tumor location in high-grade non-muscle-invasive bladder cancer"],"prefix":"10.1007","volume":"29","author":[{"given":"Ivana","family":"Vukomanovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidosav","family":"Colovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Soldatovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jovan","family":"Hadzi-Djokic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,6,9]]},"reference":[{"key":"9999_CR1","unstructured":"Konety BR, Carroll PR. Urothelial carcinoma: cancers of the bladder, ureter, & renal pelvis. In: Tanagho EA, McAninch JW, editors. Smith\u2019s general urology. 17th ed. New York: The McGraw-Hill Companies; 2008. p. 308\u201320."},{"key":"9999_CR2","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1464-410X.2005.05928.x","volume":"96","author":"TA Vogeli","year":"2005","unstructured":"Vogeli TA. The management of superficial transitional cell carcinoma of the bladder: a critical assessment of contemporary concepts and future perspectives. BJU Int. 2005;96:1171\u20136.","journal-title":"BJU Int"},{"key":"9999_CR3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ncpuro0784","volume":"4","author":"G Dalbagni","year":"2007","unstructured":"Dalbagni G. The management of superficial bladder cancer. Nat Clin Pract Urol. 2007;4:254\u201360.","journal-title":"Nat Clin Pract Urol"},{"key":"9999_CR4","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1464-410X.2004.05228.x","volume":"94","author":"E Solsona","year":"2004","unstructured":"Solsona E, Iborra I, Rubio J, Casanova J, Almenar S. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour. BJU Int. 2004;94:1258\u201362.","journal-title":"BJU Int"},{"key":"9999_CR5","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1158\/0008-5472.CAN-09-1114","volume":"69","author":"DA Zaharoff","year":"2009","unstructured":"Zaharoff DA, et al. Intravesical immunotherapy of superficial bladder cancer with Chitosan\/Interleukin-12. Cancer Res. 2009;69:6192\u20139.","journal-title":"Cancer Res"},{"key":"9999_CR6","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","volume":"53","author":"J Fernandez-Gomez","year":"2008","unstructured":"Fernandez-Gomez J, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu\u00e9rin: multivariate analysis of data from four randomized CUETO trials. Eur Urol. 2008;53:992\u20131002.","journal-title":"Eur Urol"},{"key":"9999_CR7","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","volume":"45","author":"BP Schrier","year":"2004","unstructured":"Schrier BP, Hollander MP, van Rhijn BWG, Kiemeney LALM, Witjes JA. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol. 2004;45:292\u20136.","journal-title":"Eur Urol"},{"key":"9999_CR8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000087162","volume":"75","author":"B Gunlusoy","year":"2005","unstructured":"Gunlusoy B, et al. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Gu\u00e9rin. Urol Int. 2005;75:107\u201313.","journal-title":"Urol Int"},{"key":"9999_CR9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.ju.0000070437.14275.e0","volume":"170","author":"MO Grimm","year":"2003","unstructured":"Grimm MO, et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol. 2003;170:433\u20137.","journal-title":"J Urol"},{"key":"9999_CR10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.urolonc.2005.07.005","volume":"24","author":"MS Soloway","year":"2006","unstructured":"Soloway MS. Expectant treatment of small, recurrent, low-grade, noninvasive tumors of the urinary bladder. Urol Oncol. 2006;24:58\u201361.","journal-title":"Urol Oncol"},{"key":"9999_CR11","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1097\/01.ju.0000066840.42991.4a","volume":"169","author":"M Peyromaure","year":"2003","unstructured":"Peyromaure M, et al. Intravesical bacillus Calmette-Gu\u00e9rin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. J Urol. 2003;169:2110\u20132.","journal-title":"J Urol"},{"key":"9999_CR12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-5347(05)64044-X","volume":"169","author":"O Shahin","year":"2003","unstructured":"Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Gu\u00e9rin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol. 2003;169:96\u2013100.","journal-title":"J Urol"},{"key":"9999_CR13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1464-410X.1982.tb13538.x","volume":"54","author":"NM Heney","year":"2008","unstructured":"Heney NM, et al. Ta and T1 bladder cancer: location, recurrence and progression. Br J Urol. 2008;54:152\u20137.","journal-title":"Br J Urol"},{"key":"9999_CR14","volume-title":"Intravesical immunotherapy with bacillus Calmette-Gu\u00e9rin","author":"A Bohle","year":"2000","unstructured":"Bohle A, Jocham D. Intravesical immunotherapy with bacillus Calmette-Gu\u00e9rin. Munchen, Jena: Urban & Fischer; 2000."},{"key":"9999_CR15","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.ju.0000169424.79702.6d","volume":"174","author":"J Palou","year":"2005","unstructured":"Palou J, et al. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. The J Urol. 2005;174:859\u201361.","journal-title":"The J Urol"},{"key":"9999_CR16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1464-410X.1994.tb07604.x","volume":"73","author":"PF Mulders","year":"1994","unstructured":"Mulders PF, et al. Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. Br J Urol. 1994;73:403\u20138.","journal-title":"Br J Urol"},{"key":"9999_CR17","doi-asserted-by":"crossref","unstructured":"De Souza A, Dwyer PL. Functional anatomy of the lower urinary tract. In: Dwyer PL, editor. Atlas of urogynecological endoscopy. UK: Informa healthcare; 2007. p. 7\u201317.","DOI":"10.3109\/9780203014332-3"},{"key":"9999_CR18","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.eururo.2007.07.031","volume":"53","author":"JA Pettus","year":"2008","unstructured":"Pettus JA, et al. Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. Eur Urol. 2008;53:370\u20135.","journal-title":"Eur Urol"},{"key":"9999_CR19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0094-0143(03)00060-0","volume":"30","author":"SM Donat","year":"2003","unstructured":"Donat SM. Evaluation and follow-up strategies for superficial bladder cancer. Urol Clin North Am. 2003;30:765\u201376.","journal-title":"Urol Clin North Am"},{"key":"9999_CR20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.urolonc.2008.10.022","volume":"27","author":"BH Bochner","year":"2009","unstructured":"Bochner BH. Optimal timing of radical cystectomy for patients with T1 bladder cancer. Urol Oncol Semin Orig Investig. 2009;27:329\u201331.","journal-title":"Urol Oncol Semin Orig Investig"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-011-9999-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-011-9999-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-011-9999-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T14:19:51Z","timestamp":1560262791000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-011-9999-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,9]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["9999"],"URL":"https:\/\/doi.org\/10.1007\/s12032-011-9999-4","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,9]]}}}